COCRYSTAL PHARMA INC (COCP) Stock Overview
USA - NASDAQ:COCP - US19188J4094 - Common Stock
COCP Key Statistics, Chart & Performance
The current stock price of COCP is 1.3 USD. In the past month the price decreased by -17.01%. In the past year, price decreased by -26.55%.
COCP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.75 | 714.53B | ||
| JNJ | JOHNSON & JOHNSON | 17.42 | 419.56B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.41 | 269.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.45 | 240.29B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.94 | 238.81B | ||
| MRK | MERCK & CO. INC. | 10.44 | 200.82B | ||
| PFE | PFIZER INC | 7.09 | 136.68B | ||
| SNY | SANOFI-ADR | 10.52 | 114.66B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.68 | 91.55B | ||
| GSK | GSK PLC-SPON ADR | 9.05 | 82.42B | ||
| ZTS | ZOETIS INC | 23.26 | 64.11B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.76 | 47.40B |
Related stock screener links
About COCP
Company Profile
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 11 full-time employees. The company went IPO on 2018-03-12. The firm is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). The company is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. The company has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. The company also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.
Company Info
COCRYSTAL PHARMA INC
19805 N Creek Pkwy
Bothell WASHINGTON 98011 US
CEO: Gary Wilcox
Employees: 11
Phone: 17864591831
COCRYSTAL PHARMA INC / COCP FAQ
What is the stock price of COCRYSTAL PHARMA INC today?
The current stock price of COCP is 1.3 USD. The price decreased by -2.26% in the last trading session.
What is the ticker symbol for COCRYSTAL PHARMA INC stock?
The exchange symbol of COCRYSTAL PHARMA INC is COCP and it is listed on the Nasdaq exchange.
On which exchange is COCP stock listed?
COCP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for COCRYSTAL PHARMA INC stock?
8 analysts have analysed COCP and the average price target is 7.14 USD. This implies a price increase of 449.23% is expected in the next year compared to the current price of 1.3. Check the COCRYSTAL PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is COCRYSTAL PHARMA INC worth?
COCRYSTAL PHARMA INC (COCP) has a market capitalization of 13.34M USD. This makes COCP a Nano Cap stock.
How many employees does COCRYSTAL PHARMA INC have?
COCRYSTAL PHARMA INC (COCP) currently has 11 employees.
What are the support and resistance levels for COCRYSTAL PHARMA INC (COCP) stock?
COCRYSTAL PHARMA INC (COCP) has a resistance level at 1.5. Check the full technical report for a detailed analysis of COCP support and resistance levels.
Should I buy COCRYSTAL PHARMA INC (COCP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of COCP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of COCP, evaluating the profitability, health, valuation and growth aspects
- COCRYSTAL PHARMA INC (COCP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- COCRYSTAL PHARMA INC (COCP) Sales and EPS estimates to see what analysts future expectations are.
- COCRYSTAL PHARMA INC (COCP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- COCRYSTAL PHARMA INC (COCP) Insider and Institutional Ownership to learn about the owners and their transactions.
- COCRYSTAL PHARMA INC (COCP) Stock Chart to make your own analysis
- COCRYSTAL PHARMA INC (COCP) Latest news and press-releases to stay up to date.
Does COCRYSTAL PHARMA INC (COCP) stock pay dividends?
COCP does not pay a dividend.
When does COCRYSTAL PHARMA INC (COCP) report earnings?
COCRYSTAL PHARMA INC (COCP) will report earnings on 2025-11-11, before the market open.
What is the Price/Earnings (PE) ratio of COCRYSTAL PHARMA INC (COCP)?
COCRYSTAL PHARMA INC (COCP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.24).
What is the Short Interest ratio of COCRYSTAL PHARMA INC (COCP) stock?
The outstanding short interest for COCRYSTAL PHARMA INC (COCP) is 0.63% of its float. Check the ownership tab for more information on the COCP short interest.
COCP Technical Analysis
COCP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to COCP. While COCP has a great health rating, there are worries on its profitability.
COCP Financial Highlights
Over the last trailing twelve months COCP reported a non-GAAP Earnings per Share(EPS) of -1.24. The EPS increased by 29.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -147.7% | ||
| ROE | -235.55% | ||
| Debt/Equity | 0 |
COCP Forecast & Estimates
8 analysts have analysed COCP and the average price target is 7.14 USD. This implies a price increase of 449.23% is expected in the next year compared to the current price of 1.3.